Abstract
Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 3393-3397 |
| Number of pages | 5 |
| Journal | Anticancer Research |
| Volume | 25 |
| Issue number | 5 |
| Publication status | Published - Sep 2005 |
Fingerprint
Keywords
- Colorectal cancer
- Mevalonate pathway
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Biochemical changes of mevalonate pathway in human colorectal cancer. / Caruso, Maria Gabriella; Notarnicola, Maria.
In: Anticancer Research, Vol. 25, No. 5, 09.2005, p. 3393-3397.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biochemical changes of mevalonate pathway in human colorectal cancer
AU - Caruso, Maria Gabriella
AU - Notarnicola, Maria
PY - 2005/9
Y1 - 2005/9
N2 - Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.
AB - Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.
KW - Colorectal cancer
KW - Mevalonate pathway
UR - http://www.scopus.com/inward/record.url?scp=23344432149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23344432149&partnerID=8YFLogxK
M3 - Article
C2 - 16101154
AN - SCOPUS:23344432149
VL - 25
SP - 3393
EP - 3397
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5
ER -